Q-omics provides the consensus-scored RPL7P50 profile across patient tissues and cancer cell-line models. RPL7P50 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL7P50 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPL7P50 RNA expression shows 10,531 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, KIRC, and UVM as cancer lineages where RPL7P50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7P50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7P50 survival associations across molecular data types. RPL7P50 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7P50 RNA expression–survival associations across cancer types. High RPL7P50 expression shows unfavorable associations in OV, UVM, ACC, LUAD and KIRP, but favorable associations in HNSC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify OV as the clearest survival context for RPL7P50 RNA expression.
This table summarizes RPL7P50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7P50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7P50 shows higher tumor expression in KIRC, HNSC, KIRP, COAD, LUAD and LIHC. The KIRC box plot shows higher RPL7P50 RNA expression in tumor versus normal tissue (log2 FC = +0.637, t-test p < 0.001).
This table shows molecular features associated with RPL7P50 in patient tissues and cancer cell lines. In patient samples, RPL7P50 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
